272 related articles for article (PubMed ID: 19259097)
1. Risks of myeloid malignancies in patients with autoimmune conditions.
Anderson LA; Pfeiffer RM; Landgren O; Gadalla S; Berndt SI; Engels EA
Br J Cancer; 2009 Mar; 100(5):822-8. PubMed ID: 19259097
[TBL] [Abstract][Full Text] [Related]
2. Community-acquired infections and their association with myeloid malignancies.
Titmarsh GJ; McMullin MF; McShane CM; Clarke M; Engels EA; Anderson LA
Cancer Epidemiol; 2014 Feb; 38(1):56-61. PubMed ID: 24275260
[TBL] [Abstract][Full Text] [Related]
3. The importance of evaluating specific myeloid malignancies in epidemiological studies of environmental carcinogens.
Mundt KA; Dell LD; Boffetta P; Beckett EM; Lynch HN; Desai VJ; Lin CK; Thompson WJ
BMC Cancer; 2021 Mar; 21(1):227. PubMed ID: 33676443
[TBL] [Abstract][Full Text] [Related]
4. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes.
Kristinsson SY; Björkholm M; Hultcrantz M; Derolf ÅR; Landgren O; Goldin LR
J Clin Oncol; 2011 Jul; 29(21):2897-903. PubMed ID: 21690473
[TBL] [Abstract][Full Text] [Related]
5. Incidence, survival and prevalence of myeloid malignancies in Europe.
Visser O; Trama A; Maynadié M; Stiller C; Marcos-Gragera R; De Angelis R; Mallone S; Tereanu C; Allemani C; Ricardi U; Schouten HC;
Eur J Cancer; 2012 Nov; 48(17):3257-66. PubMed ID: 22770878
[TBL] [Abstract][Full Text] [Related]
6. Relative risk of myelodysplastic syndromes in patients with autoimmune disorders in the General Practice Research Database.
Wilson AB; Neogi T; Prout M; Jick S
Cancer Epidemiol; 2014 Oct; 38(5):544-9. PubMed ID: 25189344
[TBL] [Abstract][Full Text] [Related]
7. Personal history of autoimmune disease and other medical conditions and risk of myelodysplastic syndromes.
Linabery AM; Roesler MA; Richardson M; Warlick ED; Nguyen PL; Cioc AM; Poynter JN
Cancer Epidemiol; 2022 Feb; 76():102090. PubMed ID: 34995873
[TBL] [Abstract][Full Text] [Related]
8. Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Ertz-Archambault N; Kosiorek H; Taylor GE; Kelemen K; Dueck A; Castro J; Marino R; Gauthier S; Finn L; Sproat LZ; Palmer J; Mesa RA; Al-Kali A; Foran J; Tibes R
JAMA Oncol; 2017 Jul; 3(7):936-943. PubMed ID: 28152123
[TBL] [Abstract][Full Text] [Related]
9. Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies.
Anderson LA; Gadalla S; Morton LM; Landgren O; Pfeiffer R; Warren JL; Berndt SI; Ricker W; Parsons R; Engels EA
Int J Cancer; 2009 Jul; 125(2):398-405. PubMed ID: 19365835
[TBL] [Abstract][Full Text] [Related]
10. Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d'Or (Burgundy, France).
Maynadié M; Girodon F; Manivet-Janoray I; Mounier M; Mugneret F; Bailly F; Favre B; Caillot D; Petrella T; Flesch M; Carli PM
Haematologica; 2011 Jan; 96(1):55-61. PubMed ID: 20971817
[TBL] [Abstract][Full Text] [Related]
11. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
[TBL] [Abstract][Full Text] [Related]
12. Autoimmune disease and the risk of anal cancer in the US population aged 66 years and over.
Song M; Engels EA; Clarke MA; Kreimer AR; Shiels MS
J Natl Cancer Inst; 2024 Feb; 116(2):309-315. PubMed ID: 37701981
[TBL] [Abstract][Full Text] [Related]
13. Underreporting of myeloid malignancies by United States cancer registries.
Craig BM; Rollison DE; List AF; Cogle CR
Cancer Epidemiol Biomarkers Prev; 2012 Mar; 21(3):474-81. PubMed ID: 22237987
[TBL] [Abstract][Full Text] [Related]
14. Autoimmunity and the risk of myeloproliferative neoplasms.
Kristinsson SY; Landgren O; Samuelsson J; Björkholm M; Goldin LR
Haematologica; 2010 Jul; 95(7):1216-20. PubMed ID: 20053870
[TBL] [Abstract][Full Text] [Related]
15. Physical Activity, Sitting Time, and Risk of Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Other Myeloid Malignancies.
Rees-Punia E; Patel AV; Fallon EA; Gapstur SM; Teras LR
Cancer Epidemiol Biomarkers Prev; 2019 Sep; 28(9):1489-1494. PubMed ID: 31196856
[TBL] [Abstract][Full Text] [Related]
16. Indications for bone marrow examination in autoimmune disorders with concurrent haematologic alterations.
Papageorgiou A; Ziakas PD; Tzioufas AG; Voulgarelis M
Clin Exp Rheumatol; 2013; 31(1):76-83. PubMed ID: 23010147
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.
Granfeldt Østgård LS; Medeiros BC; Sengeløv H; Nørgaard M; Andersen MK; Dufva IH; Friis LS; Kjeldsen E; Marcher CW; Preiss B; Severinsen M; Nørgaard JM
J Clin Oncol; 2015 Nov; 33(31):3641-9. PubMed ID: 26304885
[TBL] [Abstract][Full Text] [Related]
18. Autoimmune diseases and myelodysplastic syndromes.
Komrokji RS; Kulasekararaj A; Al Ali NH; Kordasti S; Bart-Smith E; Craig BM; Padron E; Zhang L; Lancet JE; Pinilla-Ibarz J; List AF; Mufti GJ; Epling-Burnette PK
Am J Hematol; 2016 May; 91(5):E280-3. PubMed ID: 26875020
[TBL] [Abstract][Full Text] [Related]
19. Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era.
Morton LM; Dores GM; Schonfeld SJ; Linet MS; Sigel BS; Lam CJK; Tucker MA; Curtis RE
JAMA Oncol; 2019 Mar; 5(3):318-325. PubMed ID: 30570657
[TBL] [Abstract][Full Text] [Related]
20. Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population-Based Study.
Wang R; Zeidan AM; Yu JB; Soulos PR; Davidoff AJ; Gore SD; Huntington SF; Gross CP; Ma X
Prostate; 2017 Apr; 77(5):437-445. PubMed ID: 27868212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
